Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation

J. E. Kiss, W. B. Rybka, A. Winkelstein, M. DeMagalhaes-Silverman, J. Lister, P. D'Andrea, E. D. Ball

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

We evaluated early and late hematopoietic reconstitution in 27 patients with advanced lymphoma, Hodgkin's disease, and breast or ovarian cancer after treatment using high-dose/myeloablative conditioning regimens and autologous peripheral blood stem cell (PBSC) transplantation. Eighteen patients (67%) received G-CSF 5 μg/kg/day following chemotherapy and nine (33%) were mobilized using G-CSF alone. Each patient had 7 x 108 mononuclear cells (MNC) per kg collected, G-CSF was administered post-PBSC infusion. While all patients showed prompt granulocyte recovery by day 14, platelet recovery failed to occur in four (15%) heavily pretreated patients with non-Hodgkin's lymphoma. Retrospective analysis in 17 patients revealed that the infused number of CD34 surface antigen-positive cells correlated with time to granulocyte (r = 0.59, P = 0.012) and platelet (r = 0.58, P = 0.021) recovery. Patients receiving the higher numbers of CD34+ cells had consistently better hematologic parameters at all times examined. At 180 days post-transplant, the median Hb level was 124 g/l vs 88 g/l (P = 0.004); platelet count was 202 x 109/l vs 25 x 109/l (P = 0.004); and neutrophil count was 3100 x 106/l vs 1400 x 106/l (P = 0.15). Hemoglobin strongly correlated with the CD34+ cell dose at 360 days (r = 0.90, P = 0.01). We conclude that graft CD34+ cell content appears to be an indicator of the quality of late as well as early hematopoietic function.

Original languageEnglish (US)
Pages (from-to)303-310
Number of pages8
JournalBone Marrow Transplantation
Volume19
Issue number4
DOIs
StatePublished - Feb 2 1997

Fingerprint

Peripheral Blood Stem Cell Transplantation
Hematopoiesis
Granulocyte Colony-Stimulating Factor
Granulocytes
Blood Platelets
CD34 Antigens
Transplants
Surface Antigens
Hodgkin Disease
Platelet Count
Ovarian Neoplasms
Non-Hodgkin's Lymphoma
Lymphoma
Hemoglobins
Neutrophils
Cell Count
Breast Neoplasms
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Kiss, J. E. ; Rybka, W. B. ; Winkelstein, A. ; DeMagalhaes-Silverman, M. ; Lister, J. ; D'Andrea, P. ; Ball, E. D. / Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. In: Bone Marrow Transplantation. 1997 ; Vol. 19, No. 4. pp. 303-310.
@article{ea1bee2faa5f40718a98ddfe065977a4,
title = "Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation",
abstract = "We evaluated early and late hematopoietic reconstitution in 27 patients with advanced lymphoma, Hodgkin's disease, and breast or ovarian cancer after treatment using high-dose/myeloablative conditioning regimens and autologous peripheral blood stem cell (PBSC) transplantation. Eighteen patients (67{\%}) received G-CSF 5 μg/kg/day following chemotherapy and nine (33{\%}) were mobilized using G-CSF alone. Each patient had 7 x 108 mononuclear cells (MNC) per kg collected, G-CSF was administered post-PBSC infusion. While all patients showed prompt granulocyte recovery by day 14, platelet recovery failed to occur in four (15{\%}) heavily pretreated patients with non-Hodgkin's lymphoma. Retrospective analysis in 17 patients revealed that the infused number of CD34 surface antigen-positive cells correlated with time to granulocyte (r = 0.59, P = 0.012) and platelet (r = 0.58, P = 0.021) recovery. Patients receiving the higher numbers of CD34+ cells had consistently better hematologic parameters at all times examined. At 180 days post-transplant, the median Hb level was 124 g/l vs 88 g/l (P = 0.004); platelet count was 202 x 109/l vs 25 x 109/l (P = 0.004); and neutrophil count was 3100 x 106/l vs 1400 x 106/l (P = 0.15). Hemoglobin strongly correlated with the CD34+ cell dose at 360 days (r = 0.90, P = 0.01). We conclude that graft CD34+ cell content appears to be an indicator of the quality of late as well as early hematopoietic function.",
author = "Kiss, {J. E.} and Rybka, {W. B.} and A. Winkelstein and M. DeMagalhaes-Silverman and J. Lister and P. D'Andrea and Ball, {E. D.}",
year = "1997",
month = "2",
day = "2",
doi = "10.1038/sj.bmt.1700671",
language = "English (US)",
volume = "19",
pages = "303--310",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "4",

}

Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. / Kiss, J. E.; Rybka, W. B.; Winkelstein, A.; DeMagalhaes-Silverman, M.; Lister, J.; D'Andrea, P.; Ball, E. D.

In: Bone Marrow Transplantation, Vol. 19, No. 4, 02.02.1997, p. 303-310.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation

AU - Kiss, J. E.

AU - Rybka, W. B.

AU - Winkelstein, A.

AU - DeMagalhaes-Silverman, M.

AU - Lister, J.

AU - D'Andrea, P.

AU - Ball, E. D.

PY - 1997/2/2

Y1 - 1997/2/2

N2 - We evaluated early and late hematopoietic reconstitution in 27 patients with advanced lymphoma, Hodgkin's disease, and breast or ovarian cancer after treatment using high-dose/myeloablative conditioning regimens and autologous peripheral blood stem cell (PBSC) transplantation. Eighteen patients (67%) received G-CSF 5 μg/kg/day following chemotherapy and nine (33%) were mobilized using G-CSF alone. Each patient had 7 x 108 mononuclear cells (MNC) per kg collected, G-CSF was administered post-PBSC infusion. While all patients showed prompt granulocyte recovery by day 14, platelet recovery failed to occur in four (15%) heavily pretreated patients with non-Hodgkin's lymphoma. Retrospective analysis in 17 patients revealed that the infused number of CD34 surface antigen-positive cells correlated with time to granulocyte (r = 0.59, P = 0.012) and platelet (r = 0.58, P = 0.021) recovery. Patients receiving the higher numbers of CD34+ cells had consistently better hematologic parameters at all times examined. At 180 days post-transplant, the median Hb level was 124 g/l vs 88 g/l (P = 0.004); platelet count was 202 x 109/l vs 25 x 109/l (P = 0.004); and neutrophil count was 3100 x 106/l vs 1400 x 106/l (P = 0.15). Hemoglobin strongly correlated with the CD34+ cell dose at 360 days (r = 0.90, P = 0.01). We conclude that graft CD34+ cell content appears to be an indicator of the quality of late as well as early hematopoietic function.

AB - We evaluated early and late hematopoietic reconstitution in 27 patients with advanced lymphoma, Hodgkin's disease, and breast or ovarian cancer after treatment using high-dose/myeloablative conditioning regimens and autologous peripheral blood stem cell (PBSC) transplantation. Eighteen patients (67%) received G-CSF 5 μg/kg/day following chemotherapy and nine (33%) were mobilized using G-CSF alone. Each patient had 7 x 108 mononuclear cells (MNC) per kg collected, G-CSF was administered post-PBSC infusion. While all patients showed prompt granulocyte recovery by day 14, platelet recovery failed to occur in four (15%) heavily pretreated patients with non-Hodgkin's lymphoma. Retrospective analysis in 17 patients revealed that the infused number of CD34 surface antigen-positive cells correlated with time to granulocyte (r = 0.59, P = 0.012) and platelet (r = 0.58, P = 0.021) recovery. Patients receiving the higher numbers of CD34+ cells had consistently better hematologic parameters at all times examined. At 180 days post-transplant, the median Hb level was 124 g/l vs 88 g/l (P = 0.004); platelet count was 202 x 109/l vs 25 x 109/l (P = 0.004); and neutrophil count was 3100 x 106/l vs 1400 x 106/l (P = 0.15). Hemoglobin strongly correlated with the CD34+ cell dose at 360 days (r = 0.90, P = 0.01). We conclude that graft CD34+ cell content appears to be an indicator of the quality of late as well as early hematopoietic function.

UR - http://www.scopus.com/inward/record.url?scp=0031044934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031044934&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1700671

DO - 10.1038/sj.bmt.1700671

M3 - Article

C2 - 9051238

AN - SCOPUS:0031044934

VL - 19

SP - 303

EP - 310

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 4

ER -